The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Unattributed - VIII | Alive

Total Raised


Last Raised

$1M | 1 yr ago

About CytImmune Sciences

CytImmune Sciences is a clinical stage nanomedicine company with a core focus on the discovery, development and commercialization of multifunctional, tumor-targeted therapies.

CytImmune Sciences Headquarter Location

15010 Broschart Road

Rockville, Maryland, 20850,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CytImmune Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CytImmune Sciences is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

838 items

CytImmune Sciences Patents

CytImmune Sciences has filed 9 patents.

patents chart

Application Date

Grant Date


Related Topics




Monoclonal antibodies, Molecular biology, Experimental cancer drugs, Peripherally selective drugs, Biotechnology


Application Date


Grant Date



Related Topics

Monoclonal antibodies, Molecular biology, Experimental cancer drugs, Peripherally selective drugs, Biotechnology



Latest CytImmune Sciences News

CytImmune Sciences Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13082018 Prices from USD $250

Oct 4, 2018

20:38 EDT 3 Oct 2018 | BioPortfolio Reports Summary CytImmune Sciences Inc CytImmune is a clinical stage nanomedicine company that discovers, develops, and commercializes tumortargeted therapies. The company develops nanotherapy platform, Aurimune, a tumortargeted trojan horse . Its Aurimune binds TNF receptors on blood vessel cells at the site of disease. CytImmune's pipeline products include CYT6091, an aurimune platform based nanomedicine that carries tumor necrosis factor into tumors to disrupt their blood vessels and enable followon chemotherapy to penetrate the tumor and kill the cancer cells inside; CYT21000, an aurimune platform based nanotherapy that carries taxol in addition to TNF. It has partnership with other oncology medicine center. The company serves patents in the US, Japan and Canada. CytImmune is headquartered in Rockville, Maryland, the US. CytImmune Sciences Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

CytImmune Sciences Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CytImmune Sciences Rank

You May Also Like

Prokaryon Technologies

Prokaryon Technologies, Inc., is a animal health company that develops solutions for the prevention and control of economically devastating diseases in food animals. The focus of the company is the discovery, development, and commercialization of veterinary products. Prokaryon's lead product is a genomics-derived vaccine to prevent shipping fever in cattle.

IVREA Pharmaceuticals

IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.


MycoTeQ discovers and develops natural antibiotics against gram-negative bacteria. The pipeline of the company is based on natural small molecules produced by microfungi. A compound library representing microfungi from a range of biological niches forms the core of the discovery process.

Chakshu Research

Led by a team with vast experience in pharmaceuticals, ophthalmology and start-ups, Chakshu Research is committed to develop pharmaceutical treatments for degenerative ocular diseases. The company are developing a self-administered eyedrop to reduce and repair oxidative damage which has been implicated in blinding degenerative diseases. While the company's drug platform is being tested on the company's lead indication, cataract; the company are also in clinical trials for glaucoma and asteroid hyalosis.

Antisense Pharma

Antisense Pharma is a biopharmaceutical company committed to researching, developing and marketing drugs that enable targeted treatment of aggressive tumor diseases. The company's main objective is to extend the life expectancy of patients considerably and, at the same time, improve quality of life.

Panacos Pharmaceuticals

Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.